b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">30086328</PMID>\n        <DateCompleted>\n            <Year>2018</Year>\n            <Month>09</Month>\n            <Day>04</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2018</Year>\n            <Month>09</Month>\n            <Day>04</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1879-3169</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>296</Volume>\n                    <PubDate>\n                        <Year>2018</Year>\n                        <Month>Oct</Month>\n                        <Day>15</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Toxicology letters</Title>\n                <ISOAbbreviation>Toxicol. Lett.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>High-mobility group box 1 protein-mediated necroptosis contributes to dasatinib-induced cardiotoxicity.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>39-47</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="pii" ValidYN="Y">S0378-4274(18)31680-1</ELocationID>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.toxlet.2018.08.003</ELocationID>\n            <Abstract>\n                <AbstractText>Dasatinib shows remarkable activity against imatinib-refractory chronic myelogenous leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph<sup>+</sup>ALL). However, severe cardiovascular toxicity limits the clinical applications of dasatinib. Since the underlying mechanism of dasatinib-induced cardiotoxicity is still elusive, we aim to clarify this. Recent studies have shown that necroptosis and apoptosis participate in multiple toxicity development. Here, we first report that dasatinib could directly induce cardiomyocytes death, as analyzed by the Sulforhodamine B (SRB) assay. This type of cardiomyocytes death was mediated by the necrosis pathway rather than apoptosis, as determined by using flow cytometry to characterize the mode of dasatinib-induced cell death. Inhibition of receptor-interacting protein kinase 1 (RIP1)activity and knockdown of receptor-interacting protein kinase 3 (RIP3)expression can block dasatinib-evoked cardiotoxicity, which further confirmed the involvement of necroptosis. We next found that the classic substrates of RIP3, mixed lineage kinase domain-like protein (MLKL) and Ca<sup>2+</sup>-calmodulin-dependent protein kinase II (CaMKII) were not involved in dasatinib-induced cardiomyocytes necroptosis. What\'s more, unlike the inflammation-associated necroptosis, dasatinib-triggered necroptosis was dependent on intracellular instead of secreted High-mobility group box 1 (HMGB1) protein. Collectively, our study revealed that dasatinib-induced cardiotoxicity acted via leading cardiomyocytes to HMGB1-mediated necroptosis, indicating a viable strategy for prevention of dasatinib-induced cardiotoxicity.</AbstractText>\n                <CopyrightInformation>Copyright \xc2\xa9 2018 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Xu</LastName>\n                    <ForeName>Zhifei</ForeName>\n                    <Initials>Z</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Institute of Pharmacology &amp; Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Jin</LastName>\n                    <ForeName>Ying</ForeName>\n                    <Initials>Y</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Institute of Pharmacology &amp; Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Yan</LastName>\n                    <ForeName>Hao</ForeName>\n                    <Initials>H</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Institute of Pharmacology &amp; Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Gao</LastName>\n                    <ForeName>Zizheng</ForeName>\n                    <Initials>Z</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Institute of Pharmacology &amp; Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Xu</LastName>\n                    <ForeName>Bo</ForeName>\n                    <Initials>B</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Institute of Pharmacology &amp; Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Yang</LastName>\n                    <ForeName>Bo</ForeName>\n                    <Initials>B</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Institute of Pharmacology &amp; Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>He</LastName>\n                    <ForeName>Qiaojun</ForeName>\n                    <Initials>Q</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Institute of Pharmacology &amp; Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Shi</LastName>\n                    <ForeName>Qiang</ForeName>\n                    <Initials>Q</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Systems Biology, National Center for Toxicological Research, Food and Drug Administration, 72079, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Luo</LastName>\n                    <ForeName>Peihua</ForeName>\n                    <Initials>P</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Institute of Pharmacology &amp; Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China. Electronic address: peihualuo@zju.edu.cn.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2018</Year>\n                <Month>08</Month>\n                <Day>04</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Netherlands</Country>\n            <MedlineTA>Toxicol Lett</MedlineTA>\n            <NlmUniqueID>7709027</NlmUniqueID>\n            <ISSNLinking>0378-4274</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="C119724">AGFG1 protein, human</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D024243">HMGB1 Protein</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="C585491">HMGB1 protein, human</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D028861">Nuclear Pore Complex Proteins</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.-</RegistryNumber>\n                <NameOfSubstance UI="C570693">MLKL protein, human</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.-</RegistryNumber>\n                <NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.11.1</RegistryNumber>\n                <NameOfSubstance UI="C119705">RIPK3 protein, human</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.11.1</RegistryNumber>\n                <NameOfSubstance UI="D053422">Receptor-Interacting Protein Serine-Threonine Kinases</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.11.17</RegistryNumber>\n                <NameOfSubstance UI="D054732">Calcium-Calmodulin-Dependent Protein Kinase Type 2</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>RBZ1571X5H</RegistryNumber>\n                <NameOfSubstance UI="D000069439">Dasatinib</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>\n                <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D054732" MajorTopicYN="N">Calcium-Calmodulin-Dependent Protein Kinase Type 2</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D066126" MajorTopicYN="N">Cardiotoxicity</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000069439" MajorTopicYN="N">Dasatinib</DescriptorName>\n                <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D024243" MajorTopicYN="N">HMGB1 Protein</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006331" MajorTopicYN="N">Heart Diseases</DescriptorName>\n                <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D032383" MajorTopicYN="N">Myocytes, Cardiac</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D009336" MajorTopicYN="N">Necrosis</DescriptorName>\n                <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D028861" MajorTopicYN="N">Nuclear Pore Complex Proteins</DescriptorName>\n                <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>\n                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName>\n                <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>\n                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016601" MajorTopicYN="N">RNA-Binding Proteins</DescriptorName>\n                <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>\n                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D053422" MajorTopicYN="N">Receptor-Interacting Protein Serine-Threonine Kinases</DescriptorName>\n                <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>\n                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Cardiotoxicity</Keyword>\n            <Keyword MajorTopicYN="N">Dasatinib</Keyword>\n            <Keyword MajorTopicYN="N">High-mobility group box 1</Keyword>\n            <Keyword MajorTopicYN="N">Necroptosis</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2018</Year>\n                <Month>05</Month>\n                <Day>29</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2018</Year>\n                <Month>08</Month>\n                <Day>01</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2018</Year>\n                <Month>08</Month>\n                <Day>02</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2018</Year>\n                <Month>8</Month>\n                <Day>8</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2018</Year>\n                <Month>9</Month>\n                <Day>5</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2018</Year>\n                <Month>8</Month>\n                <Day>8</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30086328</ArticleId>\n            <ArticleId IdType="pii">S0378-4274(18)31680-1</ArticleId>\n            <ArticleId IdType="doi">10.1016/j.toxlet.2018.08.003</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'